论文部分内容阅读
目的:用脂质体包裹新城疫病毒(NDV)修饰后的H22肝癌细胞抗原,以增进疫苗的抗肝癌效应,探讨有效的抗肝癌手段。方法:NDV感染H22肝癌细胞,氯化钾法提取肿瘤抗原,改进的机械分散法制备脂质体。80只BalB/c鼠腹腔接种H22肝癌细胞后分为2部分,每部分再用随机数字表法分4组,24 h后,分别腹腔接种脂质体包裹的H22抗原(LAg组)、脂质体包裹NDV修饰的H22抗原(LVAg组)、NDV修饰的肿瘤抗原(ND-VAg组)及D-Hanks(D-Hanks组);1周后,进行第2次免疫接种。记录小鼠的生存期。MTT法测定小鼠淋巴细胞毒活性。结果:LVAg组的抗肿瘤效应最强,其生存期为(35.2±5.5)d,脾淋巴细胞毒活性为(30.08±3.03)%,均高于其他各组,P均<0.001;LAg组的生存期为(21.6±4.2)d,优于NDVAg组(15.3±4.3)d和D-Hanks组(15.3±3.2)d,P均<0.05。LAg组脾淋巴细胞毒活性为(20.31±1.47)%,优于NDVAg组(9.38±1.53)%和D-Hanks组(9.33±1.59)%,P均<0.001。NDVAg组和D-Hanks组抗瘤效应差异无统计学意义,P>0.05。结论:NDV修饰可增强脂质体瘤苗对肝癌抗瘤作用。
OBJECTIVE: To encapsulate antigens of H22 hepatoma cells modified by Newcastle disease virus (NDV) with liposomes in order to improve the anti-hepatoma effect of the vaccine and to explore effective anti-hepatoma methods. Methods: H22 hepatoma cells were infected with NDV, tumor antigen was extracted by potassium chloride method, and liposomes were prepared by the improved mechanical dispersion method. Eighty BalB / c mice were intraperitoneally inoculated with H22 hepatocarcinoma cells and divided into two groups. Each group was divided into four groups by random number table. After 24 h, the mice were inoculated intraperitoneally with liposome-encapsulated H22 antigen (LAg group) NDV-modified H22 antigen (LVAg group), NDV modified tumor antigen (ND-VAg group) and D-Hanks group (D-Hanks group) were included in this study. One week later, the second immunization was performed. Record mouse survival. Determination of Lymphocyte Toxicity in Mice by MTT Method. Results: The anti-tumor effect of LVAg group was the strongest (35.2 ± 5.5) d, and the splenic lymphocyte cytotoxicity was (30.08 ± 3.03)%, all higher than those in other groups The survival time was (21.6 ± 4.2) d, which was better than NDVAg group (15.3 ± 4.3) d and D-Hanks group (15.3 ± 3.2) d, P <0.05. The splenic lymphocyte cytotoxicity in LAg group was (20.31 ± 1.47)%, which was superior to NDVAg group (9.38 ± 1.53)% and D-Hanks group (9.33 ± 1.59)%, P <0.001. There was no significant difference in anti-tumor effect between NDVAg group and D-Hanks group (P> 0.05). Conclusion: NDV modification can enhance the anti-tumor effect of liposome vaccine on liver cancer.